

ÕâÖֿɰ®µÄÈ«Éí±é²¼¶àÌõÉîÀ¶É«ºÍÒøÉ«ÎÆÀíµÄСÓã¶ù£¬±»ÊµÑéÈËÔ±Ç×ÇеijÆÎª¡°Ë®ÖÐС°×Êó¡±£¬ÔÚË®ÖгÉȺÓζ¯Ê±ÍðÈç³Û³ÒÔÚ²ÝÔÉϵİßÂíȺ£¬¹Ê¶øµÃÃû¡£°ßÂíÓãÊÇÒ»ÖÖ³£¼ûµÄÈÈ´øÓãÀ࣬ÆäÌåÐÍÏËϸ¡¢¸öͷС£¬³ÉÄê°ßÂíÓãÌ峤Լ4~6cm£¬2009Äê°ßÂíÓãÈ«»ùÒò×éÍê³É²âÐò£¬³ÆÎª¹«ÈϵÄÐÂÐÍģʽ¶¯ÎïÖ®Ò»¡£
×÷Ϊ³£ÓõÄģʽ¶¯Î°ßÂíÓãÓÉÓÚ¸öͷСËùÕ¼¿Õ¼äС£¬Òò´ËÏà½ÏÓÚ´óСÊó¶øÑÔ£¬°ßÂíÓãµÄËÇÑø¸üΪ±ãÀû£»¶øÇÒ£¬°ßÂíÓã·±Ö³ÄÜÁ¦Ç¿£¬²úÂÑÊý¿É´ïÊý°ÙÁ££¬Êʺϴó¹æÄ£µÄʵÑé¡£»ùÒò×é²âÐò±íÃ÷£¬°ßÂíÓãÓëÈËÀà»ùÒòµÄͬԴÐԸߴï87%£¬ÇÒÔçÆÚÅßÌ¥·¢ÓýÓëÈËÀ༫ΪÏàËÆ£»ÔÚµ°°×ÖÊˮƽÉÏ£¬¹Ø¼ü²¿Î»µÄͬԴÐÔ¼¸ºõÊÇ100%¡£ÊÇÑо¿ÒÅ´«¡¢·¢ÓýµÈÉúÎïҽѧÁìÓòµÄ×î¼ÑģʽÉúÎïÖ®Ò»¡£
°ßÂíÓã´ÆÐÛ¼ø±ð£ºÐÛÓãµÄÓãÌåÐÞ³¤£¬ÌåÉ«ÂÔÉÉîÀ¶É«ÌõÎÆ¼ä»ÆÉ«ÌõÎÆÇÒÌõÎÆÃ÷ÏÔ£»´ÆÓãµÄÓãÌå½ÏΪ·Ê˶£¬Ìåɫƫµ£¬À¶É«ÌõÎÆ¼äÒø»ÒÉ«ÌõÎÆ£¬¸¹²¿·Ê´ó£¬Óȼû»³ÂÑÆÚÓ㸹Åò´ó¡£

£¨Í¼£ºÊµÑéÊÒ°ßÂíÓãËÇÑø£»Í¼Æ¬Ô´ÓÚÍøÂ磩

£¨Í¼£º°ßÂíÓã´ÆÐÛ¼ø±ð£»Í¼Æ¬Ô´ÓÚÍøÂ磩

°ßÂíÓãÌåÍâÊܾ«¡¢ÌåÍâ·¢Óý¡¢Åß̥͸Ã÷¡¢Éú³¤¿ìÇÒÉúÃüÖÜÆÚ¶Ì¡£ÅßÌ¥·¢Óý¾ÀúºÏ×ÓÆÚ£¨0~0.75h£©¡úÂÑÁÑÆÚ£¨0.75~2.25h£©¡úÄÒÅßÆÚ£¨2.25~5.25h£©¡úÔ³¦ÆÚ£¨5.25~10h£©¡úÌå½ÚÆÚ£¨10~24h£©¡úÑÊÄÒÆÚ£¨24~48h£©¡ú·õ»¯ÆÚ£¨48~72h£©¡úÔçÓ×ÆÚ£¨CHARLES B, KIMMEL, WILLIAM W, BALLARD, SETH RµÈ£©


£¨Í¼£º°ßÂíÓãÅßÌ¥·¢Óý¹ý³Ì£©

Ŀǰ£¬°ßÂíÓãÔÚ·¢ÓýÒÅ´«Ñ§¡¢Éú̬¶¾Àíѧ¡¢ÈËÀ༲²¡Ä£ÐÍ¡¢»ùÒòËðÉ˺ÍÐÞ¸´¡¢Ò©ÎïɸѡµÈÁìÓò¾ùÓй㷺ӦÓ᣼øÓÚÎÄÕÂÆª·ùÏÞÖÆ£¬±àÕ߾ͰßÂíÓãÔÚ¶¾Àí¡¢Ö×ÁöÒÔ¼°Ò©Îïɸѡ·½Ãæ×öÒ»¼òµ¥½éÉÜ¡£
3.1°ßÂíÓãÔÚ¶¾ÀíѧÁìÓòµÄÓ¦ÓÃ
°ßÂíÓã×îÔç±»ÓÃÓÚË®Ìå¼à²â¡¢Ö»û¼°ÆäËûÓж¾ÎïÖʵļì²â£¬ÒѾ³ÉΪҩÎﰲȫÐÔÆÀ¼Û¡¢Éú̬¶¾ÐÔ·ÖÎö¡¢»·¾³·çÏÕÆÀ¹ÀµÄÓÐЧģʽ¶¯ÎŷÖÞ»¯×±Æ·¶¾ÀíѧºÍÉú̬¶¾ÀíѧÖÐÐÄ£¨ECETOC£©¡¢¾¼ÃºÏ×÷Óë·¢Õ¹×éÖ¯£¨OECD£©ºÍ¹ú¼Ê±ê×¼»¯×éÖ¯£¨ISO£©ÕâЩȨÍþ×éÖ¯ÒѾÈϿɰßÂíÓãÔÚ¶¾ÀíѧÖеļÛÖµ£»Nisha S. Sipes½«°ßÂíÓã³ÆÎª¡°21ÊÀ¼ÍÐÂÐ͵;ÐÔ²âÊÔÄ£ÐÍ¡±¡£Ó벸È鶯ÎïÏà±È£¬°ßÂíÓã×î´óÓÅÊÆÊǽøÐиßͨÁ¿É¸Ñ¡£¬¿ÉÔÚϸ°ûˮƽʵÏÖ¶Ô¶¾ÎïµÄ¶¾ÐÔÔ¤²â£»´ËÍ⣬ÓÉÓÚ°ßÂíÓãÅßÌ¥¼¸ºõ͸Ã÷£¬Òò¶ø¿ÉÒÔ½èÖúÏÔ΢¾µÖ±¹Û¹Û²ìÅßÌ¥µÄ¸÷½×¶Î·¢ÓýÇé¿ö£¬Ã÷È·¶¾ÎïµÄ×÷Óðе㣬°ßÂíÓãÅßÌ¥ÔÚ¶¾ÀíѧÑо¿ÖгÉΪµ±Ç°Èȵ㡣
±í °ßÂíÓãÅßÌ¥·¢Óý¿É¹Û²ìµ½µÄ¶¾ÀíѧÖÕµã

£¨±í¸ñÀ´Ô´ÓÚÖйúũҵ¿ÆÑ§Ôº ÂÀÅô[1]£©
ÓÉÓÚ°ßÂíÓãµÄÅßÌ¥ÌØÐÔ£¬Ê¹µÃÉúÎï³ÉÏñ¼¼ÊõÔÚ°ßÂíÓãÅßÌ¥·¢Óý¹ý³ÌÖб»´óÁ¿Ó¦Óá£ÉúÎï³ÉÏñ¼È¿ÉÒÔͨ¹ýÏÔ΢¾µÖ±½Ó¹Û²ì£¬Ò²¿ÉÒÔÍâ¼ÓÓ«¹â¼Á»òÕ߸¨ÒÔ»ùÒòÊֶμÓÈëÓ«¹âµ°°×±í´ïµÄ»ùÒò£¬Í¨¹ýÓ«¹â³ÉÏñ¼à²â¸Ã»ùÒòµÄ±í´ï¡£

£¨Í¼£ºÌ¼Á¿×ÓµãÔÚ°ßÂíÓãÌåÄÚµÄË¥¼õ¹ý³Ì£»Õž°»Û[2]£©

£¨Í¼£ºÊ¯Ä«Ï©Á¿×Óµã¶Ô°ßÂíÓãµÄ·¢Óý¶¾ÐÔÑо¿. A:Õý³£Ó㣻B~D£º±©Â¶ÓÚʯīϩÁ¿×ÓµãµÄ»ûÐÎÓã¡£ PE£ºÐÄÄÒË®Ö×£»VC£ºÂÑ»ÆÄÒÖ×£¬BS£º¼¹ÖùÍäÇú£»Õž°»Û[2]£©
°ßÂíÓãÅßÌ¥ÔÚÄÉÃ׿ÅÁ£µÄ¶¾ÐÔÑо¿ÁìÓòÖÐͬÑùÔËÓûðÈÈ¡£Haissam Abou-Saleh[3]µÈÈËÔËÓÿǾÛÌÇÄÉÃ׿ÅÁ£¶Ô°ßÂíÓãÅßÌ¥½øÐÐÁ˶¾ÐÔÑо¿£¬·¢ÏֿǾÛÌÇÄÉÃ׿ÅÁ£²¢²»Ó°Ïì°ßÂíÓãÅßÌ¥µÄ´æ»î¡£

£¨Í¼£ºChNPs×飺¿Ç¾ÛÌÇÄÉÃ׿ÅÁ££¬ÔÚ200mg/LŨ¶ÈÏÂÅßÌ¥·¢Óýδ¼ûÒì³££»DEAB×飺¶þ¼×°±»ù±½¼×È©£¬ÌåÐÍС¡¢¼¹Öù²à͹µÄÐÄÔàË®Ö×£¨·â±Õ¼ýÍ·£©¡¢ÂÑ»ÆÄÒÖ×£¨¿ª·Å¼ýÍ·£©£»Haissam Abou-Saleh, et al[3]£©
°ßÂíÓãÒѱ»Å·ÖÞʵÑéÌæ´úÑо¿ÖÐÐÄÍÆ¼öΪеÄÌæ´ú¶¯Î³ÉΪ21ÊÀ¼ÍÒ»¸ö¸ßЧ¶øÆÕÊʵĻ·¾³¶¾ÀíѧģʽÉúÎ¿ÉÒÔ½øÐжàά¶ÈµÄÉú̬·çÏÕÆÀ¹À£¬ÔÚÓÅ»¯ºÍ¼õÉÙ²¸È鶯ÎïÌåÄÚÊÔÑé¼°»·¾³»¯Ñ§Îï¶¾ÐÔ×÷ÓûúÖÆÊÔÑéÖоßÓÐÖØ´ó¼ÛÖµ¡£
3.2 °ßÂíÓãÔÚÖ×ÁöÄ£ÐÍÖеÄÓ¦ÓÃ
ÔÚ°©Ö¢Ñо¿·½Ã棬°ßÂíÓãÄ£ÐÍÓ봫ͳµÄϸ°ûÅàÑø·½·¨Ïà±È¸ü¾ßÓÐÓÅÊÆ£¬ÒòΪ°ßÂíÓã¿ÉÒÔ²âÊÔ¸ü¹ã·ºµÄ±íÐÍ¡£°ßÂíÓãºÍ²¸È鶯ÎïÔÚÖ×ÁöµÄ½øÕ¹¹ý³ÌÖÐÓй²Í¬µÄ·Ö×Ó;¾¶£¬°ßÂíÓã¸ÎÖ×ÁöÖÐÓг¬¹ý130ÖÖ²»Í¬µÄ»ùÒò±íÏÖ³öÓëÈËÀà¸Î°©ÏàËÆµÄ±í´ï£¬ÓëÖ×Áö×é֯ѧÀàÐÍ¡¢·Ö¼¶ºÍ·ÖÆÚÓйء£ZhengºÍËûµÄͬÊÂÃÇÖ¤Ã÷ÁËת»ùÒò°ßÂíÓãÄ£ÐÍÓëÈËÀà¸Îϸ°û°©¾ßÓÐÏàͬµÄ·Ö×Ó±ê¼Ç[4]¡£Óм¸ÖÖ·½·¨¿ÉÒÔÔÚ°ßÂíÓãÌåÄÚ¸´ÖÆÈËÀà°©Ö¢£¬±ÈÈçÀûÓÃÍ»±äϵºÍת»ùÒòÒÔ¼°Ö×Áöϸ°ûµÄÒÆÖ²¡£

£¨Í¼£º°ßÂíÓã³ÉÌåºÍÅßÌ¥°©±ä·¢ÉúµÄ·½·¨£»Patricia Letrado, et al[5]£©

£¨Í¼£º°ßÂíÓãÖ×ÁöÒÆÖ²£»Patricia Letrado, et al[5]£©

£¨Í¼£º°ßÂíÓãÓ×ÌåÒìÖÖÒÆÖ²·¢ÓýʾÒâͼ£¬Nusrat Khan, et al[6]£©

£¨Í¼£º°ßÂíÓã³ÉÌåÒìÖÖÒÆÖ²·¢ÓýʾÒâͼ£»Nusrat Khan, et al[6]£©

£¨Í¼£ºU937°×Ѫ²¡Ï¸°ûÒìÖÖÒÆÖ²ÔÚÓ×ÌåÆÚ¡£Ã¿Ö»Ó×Ìå×¢Éä300~500¸öU937ϸ°ûÔÚ24¡¢72hºó°ßÂíÓãÓ×Ìå±íÏÖ³öµÄµäÐÍÁÁ³¡ºÍÓ«¹âͼÏñ¡£Nusrat Khan, et al[6]£©

£¨Í¼£º×ó²àHuh7ϸ°ûÒÆÖ²³ÉÓãµÄ´ú±íÐÔͼÏñÏÔÊ¾ÒÆÖ²ºó15ÌìÒìÖÖÒÆÖ²ÎïÔÚ¸¹Ç»·¢Óý£»ÓÒ²àΪÐÄÔàÄÚ×¢ÉäU937ϸ°ûÏÔʾÁËÕâЩϸ°ûÔÚÒÆÖ²ºó15Ì춨λµ½¸¹Ç»¡£Nusrat Khan, et al[6]£©
Ŀǰ£¬²ÉÓÃת»ùÒò¡¢Õý/·´ÏòÒÅ´«Ñ§¡¢ÒÆÖ²¡¢»¯Ñ§ÓÕµ¼µÈÏÖÓм¼Êõ£¬¿ÉÒԳɹ¦µÄ¶Ô°ßÂíÓã½øÐв»Í¬Ö×ÁöÄ£Ð͵Ĺ¹½¨¼°»úÖÆÑо¿£¬ÀýÈçºÚÉ«ËØÁöÖ×Áö¡¢¸Î°©¡¢Æ¤·ô°©¡¢Ñª¹ÜÁö¡¢Ï¸°û¼äÖÊÁö¡¢¹¬¾±°©¡¢ÒÈÏÙÖ×Áö¡¢Ä³Ð©×ªÒÆÁö¡¢Éñ¾Ä¸Ï¸°ûÁö¼°ÉÏÎÄÌáµ½µÄ°×Ѫ²¡Ä£Ð͵ȣ¬²»Í¬°ßÂíÓãÖ×ÁöÄ£Ð͵Ŀª·¢£¬ÎªÏà¹ØÁìÓòµÄÉîÈëÑо¿ÌṩÁ˸üÇ¿´óµÄÖ§³Å¡£
3.3°ßÂíÓãÔÚÒ©ÎïɸѡÖеÄÓ¦ÓÃ
½üÄêÀ´£¬°ßÂíÓã¼²²¡Ä£ÐÍÒÑÓкܶàÑо¿³É¹û£¬»ùÓÚ°ßÂíÓã¼²²¡Ä£Ð͵ÄÒ©ÎïɸѡҲÕýÈç»ðÈçݱµÄ¿ªÕ¹£¬²¢ÒѾ³É¹¦µØÓ¦Óõ½ÖÎÁÆÖîÈçÖ×Áö¡¢Éñ¾¡¢ÐÄѪ¹Ü¡¢ÑÛ¿Æ¡¢¹Ç÷ÀµÈ¼²²¡µÄÒ©ÎïɸѡÖС£
¸´µ©´óѧµÄÖÓÌÎ[7]Ñо¿ÍŶÓÓÃת»ùÒò°ßÂíÓã½øÐÐÁ˾ßÓе÷¿ØÐļ¡·¢Óý·Ö»¯»îÐÔµÄÏȵ¼»¯ºÏÎïɸѡ£¬¼ø¶¨³öÒ»ÀàÄܹ»Ôö¼Ó°ßÂíÓãÐļ¡Ï¸°ûµÄС·Ö×Ó»¯ºÏÎïCardionogen.

£¨Í¼£ºÓ°ÏìÐÄÔà·¢ÓýµÄ»¯ºÏÎïɸѡ¹ý³ÌµÄʾÒâͼ£»3¸ö±»TG(cmlc2-EGFP)±ê¼ÇµÄÅßÌ¥×ªÒÆµ½Ã¿¸öº¬10 ?M E3»º³åÒºµÄ¿×ÖÐ[7]£©

£¨Í¼£º°ßÂíÓã·¢Óý¹ý³ÌÖÐCardionogen¿ÉÔö¼ÓÐÄÔà´óС¡£A£ºCardionogen¼Ò×åµÄ»¯Ñ§½á¹¹£»B£ºÎ´¾´¦ÀíµÄ¶ÔÕÕ×é°ßÂíÓãÐÄÔࣻC£ºCDNG1´¦ÀíµÄÐÄÔࣻD£ºCDNG2´¦ÀíµÄÐÄÔࣻE£ºÎ´¾´¦ÀíµÄ¶ÔÕÕ×éÅßÌ¥£»F£ºÔÚ60hpfʱµÄCDNG1´¦ÀíµÄ±»TG(cmlc2-EGFP)±ê¼ÇµÄÅßÌ¥£»G£º¶ÔÕÕ×éÅßÌ¥£»H£º60hpfʱ±»CDNG1´¦ÀíµÄÅßÌ¥¡£B-DΪ¸¹²à¹Û£»E-HΪ×ݲà¹Û[7]£©
ÁíÓÐѧÕßÀûÓðßÂíÓãɸѡ³ö¶Ô°×Ѫ²¡ÓÐÑ¡ÔñÐÔ¶¾ÐÔµÄÐÂÐÍ»¯ºÏÎï¡£

£¨Í¼£º°ßÂíÓãÒ©Îïɸѡ¼ø¶¨¿¹Tϸ°û»¯ºÏÎï[8]£©
ÔÚÒ©ÎïɸѡÖУ¬ÌåÍâϸ°ûˮƽ×÷Óû·½Úµ¥Ò»£¬Äö³ÝÀදÎïʵÑéÀͶ¯Ç¿¶È´ó£¬³É±¾¸ß£¬ÀûÓðßÂíÓãÄ£ÐÍÄÜÓÐЧ¸øÓèÃÖ²¹¡£ÓÐÒ»ÖÖÉíÌåÍêȫ͸Ã÷µÄ°ßÂíÓãÔÚ¶àÄêǰ¾ÍÒѱ»ÃÀ¹ú¿ÆÑ§¼Ò³É¹¦ÅàÓý³öÀ´£¬ÕâÖÖ͸Ã÷°ßÂíÓã¸ü·½±ã¹Û²ìÆäÄÚ²¿½á¹¹£¬Òò¶ø¸üÓÐÀû¼à²âÖ×ÁöµÄ·¢Éú·¢Õ¹¡£µ±È»£¬°ßÂíÓãÄ£ÐÍÒ²ÓÐijЩ¾ÖÏÞ£¬ÀýÈç°ßÂíÓã¶ÔÒ©ÎïµÄ´úлÓëÈËÀ಻ÍêÈ«Ïàͬ£¬Í¨¹ý°ßÂíÓãÄ£ÐÍɸѡµÃµ½µÄÏȵ¼»¯ºÏÎïÒÀÈ»±ØÐëÔÚºÏÊʵÄÄö³ÝÀදÎïÄ£ÐÍÖнøÐÐÑéÖ¤£¬µ«ÊǰßÂíÓã×÷ΪҩÎïɸѡģÐÍÒÑÏÔʾ³ö¾Þ´óµÄDZÁ¦£¬ÔÚÒ©Îïɸѡ·½Ãæ±Ø½«½øÒ»²½ÉîÈëºÍÍêÉÆ¡£

£¨È«Éí͸Ã÷µÄ°ßÂíÓ㣻ͼƬԴÓÚÍøÂ磩
×Ô20ÊÀ¼Í90Äê´ú³õÒÔÀ´£¬°ßÂíÓãÒòÆäÖî¶àÓŵãÒѳÉΪģʽ¶¯Îï¼Ò×åÖм«ÆäÖØÒªµÄÒ»Ô±£¬µÃµ½Á˸߶ÈÖØÊӺ͹㷺ÔËÓᣳýÁËÉÏÎÄÖÐËùÌáµ½µÄ£¬°ßÂíÓ㻹ÔÚÉñ¾ÏµÍ³¼²²¡ÈçAD¡¢PD£»ÐÄѪ¹Ü¼²²¡¡¢ÌÇÄò²¡¡¢·ÊÅÖ¡¢ÊÓÍøÄ¤¼²²¡ÒÔ¼°¹âƬÏÔ΢³ÉÏñ¼¼ÊõµÈÁìÓò¾ùÓм«´óµÄÑо¿¼ÛÖµ£¬ÏàÐÅËæ×Å¿ÆÑ§µÄ½ø²½£¬°ßÂíÓ㻹½«²»¶Ï¸øÈËÃÇ´øÀ´¾ªÏ²¡£

²Î¿¼ÎÄÏ×£º
[1]ÂÀÅô. ÒìàçßòßøÍªÀàÑÜÉúÎï¶Ô°ßÂíÓãÅßÌ¥·¢ÓýµÄ¶¾ÀíѧÑо¿[D]. ±±¾©£ºÖйúũҵ¿ÆÑ§Ôº£¬2018:1-101.
[2]Õž°»Û. ̼»ùÁ¿×ÓµãµÄÖÆ±¸Óë°ßÂíÓãÓ«¹â³ÉÏñµÄÓ¦Óü°Ïà¹Ø¶¾ÀíµÄÑо¿[D]. ºÓÄÏ£ºÖ£ÖÝ´óѧ£¬2017:1-71.
[3]Abou-Saleh H, Younes N, Rasool K, et al. Impaired Liver Size and Compromised Neurobehavioral Activity are Elicited by Chitosan Nanoparticles in the Zebrafish Embryo Model[J]. Nanomaterials, 2019, 9, 122; doi:10.3390/nano9010122.
[4] Zheng W, Li Z, Nguyen AT, Li C, Emelyanov A, Gong Z. Xmrk, Kras and Myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma[J]. PLoS One, 2014;9:e91179.
[5]Letrado P, Miguel ID, Lamberto I,et al. Zebrafish: Speeding Up the Cancer Drug Discovery Process[J]. Cancer Res, 2018,78(21) :6048-6058.
[6] Khan N, Mahajan NK, Sinha P, Jayandharan GR. An efficient method to generate xenograft tumor models of acute myeloid leukemia and hepatocellular carcinoma in adult zebrafish[J]. Blood Cells, Molecules and Diseases, 2019, 75:48-55.
[7]Ni TT, Rellinger EJ, Mukherjee A, et al. Discovering small molecules that promote cardiomyocyte generation by modulating Wnt signaling[J]. Chem Biol , 2011, 18(12): 1658¨C1668. doi:10.1016/j.chembiol.2011.09.015.
[8]Ridges S, Heaton WL, Joshi D, et al. Zebrafish screen identifies novel compound with selective toxicity against leukemia[J]. Blood, 2012, 119(24): 5621-5631.
